ADI Launches the Alzheimer’s Disease Atlas
Access the world's first of its kind platform highlighting how countries diagnose, treat and support people living with dementia.
News
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Featured news
Highlights from the National Dementia Plan Pan Regional Workshop 2026
Government representatives, dementia associations and WHO experts gathered in London to share progress, tackle challenges and strengthen collaboration on developing and implementing effective National Dementia Plans worldwide.
Civil Society and Lawmakers Push Forward Argentina’s National Alzheimer Law in San Juan
In June, ADI’s Regional Director for the Americas, Diego Aguilar, attended a national meeting of Alzheimer’s associations in San Juan, Argentina. The meeting sought to unite lawmakers, civil society, healthcare professionals and more from across Argentina in an effort to call for legislation surrounding Alzheimer’s under the banner of #LeyAlzheimerYa (#AlzheimersLawNow).
Revisiting the World Alzheimer Report 2024: Challenging dementia stigma in popular culture & why we need media guidelines
Perceptions of dementia are dependent on many factors, such as direct personal experience with a loved one having the condition or exposure to public information campaigns, for example. Popular culture also plays a role in shaping the public discourse around dementia in ways that can have significant consequences on the…
UK National Health Service to deny free Alzheimer’s treatments
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.
Revisiting the World Alzheimer Report 2024: Becoming an advocate and a force for change as an LGBTQ+ person with early-onset dementia
Challenging dementia stigma is one of ADI’s core missions, and one where there is unfortunately still a long way to go. ADI’s global survey on attitudes to dementia in 2024 revealed that a worrying 80% of the general public still thinks that dementia is a normal part of ageing,…
Spotlight on Asia Pacific: Research, Advocacy and Awards
In May, ADI’s Regional Director for the Asia Pacific Region, DY Suharya travelled to Sydney, Australia to participate in the launch of the e-DiVA programme alongside representatives from Australia, New Zealand, Indonesia, and Viet Nam. Then, ADI Board Member and Executive Vice President of ADI member Alzheimer’s Disease Chinese, Professor Huali Wang, was one of the six public health champions celebrated at the 78th World Health Assembly later in the month.
Dementia advocacy in the Americas: Strengthening policy and public awareness
From in-person high level engagements in Lima to Buenos Aires, to a digital campaign partnership providing regionally specific resources, May has proven to be an action-packed month in the Americas region. ADI Regional Director for the America’s provides his highlights from across the region including advocacy work in Argentina and Peru, alongside a public awareness campaign in partnership with the Carlos Slim Foundation.
The 78th World Health Assembly agrees to extend the Global Action Plan on the Public Health Response to Dementia
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
Donanemab Receives Marketing Authorisation in Australia, Brazil, and Mexico
Marketing authorisation has been granted for donanemab (Kisunla) in Australia, following announcements from Brazil, and Mexico, for the treatment of Alzheimer's disease. The authorisations in Brazil and Mexico were granted in April 2025, with the announcement of the Australian approval on 21 May 2025.